Bristol-Myers Squibb will maintain strategic
presence in Italy through ongoing development and commercialization
of new medicines
Catalent will continue to manufacture
products for Bristol-Myers Squibb while offering other customers
access to state-of-the-art sterile biologics fill/finish and oral
solids manufacturing and packaging platforms
Bristol-Myers Squibb Company (NYSE:BMY) and Catalent, Inc.
(NYSE: CTLT), today announced that Catalent has agreed to purchase
Bristol-Myers Squibb’s oral solid, biologics, and sterile product
manufacturing and packaging facility in Anagni, Italy. Catalent is
the leading global provider of advanced delivery
technologies, development and manufacturing solutions for
drugs, biologics, gene therapies, and consumer health products. The
companies anticipate completing the transaction by the end of 2019,
subject to regulatory approvals, the information and consultation
procedure with the unions, and the satisfaction of certain other
customary closing conditions.
Through the years, the Anagni plant has served as one of the
primary launch facilities for new medicines from Bristol-Myers
Squibb that have helped millions of people in the fight against
serious diseases such as cancer and cardiovascular disease. Upon
closing, Catalent will continue to manufacture Bristol-Myers
Squibb’s current product portfolio at the site.
By enhancing its own global network with the Anagni plant,
Catalent will bring potential new customers to the site for both
biologics and oral solid dose manufacturing and packaging. In
particular, this facility will provide Catalent biologics customers
with access to an advanced sterile drug product fill/finish and
packaging capacity in Europe to complement its existing sterile
fill/finish capabilities in Belgium and its drug substance,
analytical and fill/finish capabilities in North America.
“We believe that the sale to Catalent will continue the vital
role the Anagni facility plays for its workforce, the community and
patients,” said Lou Schmukler, President, Global Product
Development and Supply, Bristol-Myers Squibb. “This marks an
important step in the ongoing evolution of our manufacturing
network to support the company’s innovative product portfolio.
Bristol-Myers Squibb has a long history in Italy, and we intend to
maintain a continued strategic presence in Italy, which is critical
for our ability to deliver transformational medicines to
patients.”
Alessandro Maselli, Catalent’s President and Chief Operating
Officer, commented, “The addition of the Anagni facility provides
our European customers with great biologics and oral dose
capabilities to accelerate their development programs and improve
commercial supply.” He added, “Bristol-Myers Squibb has invested in
the facility to create a center of excellence for new product
launches with a robust quality and delivery record, and an employee
base who shares Catalent’s operational excellence and patient
focus.”
William Blair & Company served as financial advisor to
Bristol-Myers Squibb.
About the Anagni Facility
The Bristol-Myers Squibb Anagni facility is a pharmaceutical
manufacturing plant, situated in an industrial area one hundred
kilometers southeast of Rome. The site opened in 1966. The facility
floor space is approximately 19,300 square meters on a site of 34
hectares. The Anagni facility manufactures and packages
cardiovascular, neuroleptics, anticancer, metabolic and
anti-inflammatory medicines as well as non-penicillin-based
antibiotics, antivirals, analgesics as injectables and
biologics.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter, YouTube and Facebook.
About Catalent
Catalent is the leading global provider of advanced delivery
technologies, development and manufacturing solutions for drugs,
biologics, gene therapies, and consumer health products. With over
85 years serving the industry, Catalent has proven expertise in
bringing more customer products to market faster, enhancing product
performance and ensuring reliable global clinical and commercial
product supply. Catalent employs over 11,000 people, including over
1,800 scientists, at more than 30 facilities across five
continents, and in fiscal year 2018 generated over $2.5 billion in
annual revenue. Catalent is headquartered in Somerset, New Jersey.
For more information, visit www.catalent.com.
More products. Better treatments. Reliably supplied.™
Bristol-Myers Squibb Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995
regarding, among other things, the research, development and
commercialization of pharmaceutical products and the proposed
transaction. All statements that are not statements of historical
facts are, or may be deemed to be, forward-looking statements. Such
forward-looking statements are based on historical performance and
current expectations and projections about our future financial
results, goals, plans and objectives and involve inherent risks,
assumptions and uncertainties, including internal or external
factors that could delay, divert or change any of them in the next
several years, that are difficult to predict, may be beyond our
control and could cause our future financial results, goals, plans
and objectives to differ materially from those expressed in, or
implied by, the statements. These risks, assumptions, uncertainties
and other factors include, among others, the completion of the
information and consultation processes with relevant employee
representative bodies in connection with the proposed transaction,
the parties’ ability to satisfy certain closing conditions, any
delay or inability of Bristol-Myers Squibb to realize the expected
benefits of the proposed transaction and that the proposed
transaction will close on the terms or within the time frame
described in this document. No forward-looking statement can be
guaranteed. Forward-looking statements in this press release should
be evaluated together with the many risks and uncertainties that
affect Bristol-Myers Squibb's business and market, particularly
those identified in the cautionary statement and risk factors
discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for
the year ended December 31, 2018, as updated by our subsequent
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and
other filings with the Securities and Exchange Commission. The
forward-looking statements included in this document are made only
as of the date of this document and except as otherwise required by
applicable law, Bristol-Myers Squibb undertakes no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events, changed circumstances
or otherwise.
Catalent Forward-Looking Statement Notice
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995
regarding, among other things, the research, development and
commercialization of pharmaceutical products and the proposed
transaction. All statements that are not statements of historical
facts are, or may be deemed to be, forward-looking statements. Such
forward-looking statements are based on historical performance and
current expectations and projections about our future financial
results, goals, plans and objectives and involve inherent risks,
assumptions and uncertainties, including internal or external
factors that could delay, divert or change any of them in the next
several years, and could cause our future financial results, goals,
plans and objectives to differ materially from those expressed in,
or implied by, the statements. These risks, assumptions,
uncertainties and other factors include, among others, the
completion of the information and consultation processes with
relevant employee representative bodies in connection with the
proposed transaction, the parties’ ability to satisfy certain
closing conditions, any delay or inability of Catalent to realize
the expected benefits of the proposed transaction and whether the
proposed transaction will close on the terms or within the time
frame described in this press release. No forward-looking statement
can be guaranteed. Forward-looking statements in this press release
should be evaluated together with the many uncertainties that
affect Catalent’s business, particularly those identified in the
risk factors discussion in Catalent’s Annual Report on Form 10-K
for the year ended June 30, 2018 and other filings by Catalent with
the Securities and Exchange Commission. The forward-looking
statements included in this press release are made only as of the
date of this press release, and, except as otherwise required by
federal securities law, Catalent undertakes no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events, changed circumstances
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190619005061/en/
Bristol-Myers Squibb
Media:U.S. – Priyanka Shah, +1-609-252-7602,
Priyanka.shah1@bms.comItaly – Antonella Iacovelli, 0039-348521107,
antonella.iacovelli@bms.com
Investors:Tim Power, +1-609-252-7509,
timothy.power@bms.com
Catalent, Inc.
Media:Chris Halling, +44 (0)7580 041073,
chris.halling@catalent.comRichard Kerns, NEPR, +44 (0)161 728
5880
Investors:Tom Castellano, +1-732-537-6175,
thomas.castellano@catalent.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024